MCID: HYP602
MIFTS: 37

Hyperoxaluria, Primary, Type Ii

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Metabolic diseases

Aliases & Classifications for Hyperoxaluria, Primary, Type Ii

MalaCards integrated aliases for Hyperoxaluria, Primary, Type Ii:

Name: Hyperoxaluria, Primary, Type Ii 53 13 51
Glyoxylate Reductase/hydroxypyruvate Reductase Deficiency 53 23 49 71
D-Glycerate Dehydrogenase Deficiency 53 49 55 71
Primary Hyperoxaluria Type 2 23 49 55 69
Glyceric Aciduria 53 49 71
Hp2 53 49 71
L-Glyceric Aciduria 55 71
Oxalosis Ii 53 71
Glyoxylate Reductase/hydroxypyruvate Reductase 13
Primary Hyperoxaluria, Type Ii 28
Hyperoxaluria Primary Type Ii 71
Primary Hyperoxaluria Type Ii 71
Hyperoxaluria Primary 2 71
Oxalosis 2 49
Ph2 71

Characteristics:

Orphanet epidemiological data:

55
primary hyperoxaluria type 2
Inheritance: Autosomal recessive; Age of onset: Childhood; Age of death: any age;

OMIM:

53
Inheritance:
autosomal recessive

Miscellaneous:
variable severity
some patients may be asymptomatic
onset usually in infancy or early childhood


HPO:

31
hyperoxaluria, primary, type ii:
Onset and clinical course variable expressivity
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 53 260000
Orphanet 55 ORPHA93599
UMLS via Orphanet 70 C0268165
ICD10 via Orphanet 33 E74.8
MedGen 39 C0268165
MeSH 41 D006960
UMLS 69 C0268165

Summaries for Hyperoxaluria, Primary, Type Ii

NIH Rare Diseases : 49 Primary hyperoxaluria type 2  is a rare condition characterized by the overproduction of a substance called oxalate (also called oxalic acid). In the kidneys, the excess oxalate combines with calcium to form calcium oxalate, a hard compound that is the main component of kidney stones. Deposits of calcium oxalate can lead to kidney damage, kidney failure, and injury to other organs. Primary hyperoxaluria type 2 is caused by the shortage (deficiency) of an enzyme called glyoxylate reductase/hydroxypyruvate reductase (GRHPR) that normally prevents the buildup of oxalate. This enzyme shortage is caused by mutations in the GRHPR gene. Primary hyperoxaluria type 2 is inherited in an autosomal recessive pattern. Last updated: 1/3/2013

MalaCards based summary : Hyperoxaluria, Primary, Type Ii, also known as glyoxylate reductase/hydroxypyruvate reductase deficiency, is related to d-glyceric aciduria and primary hyperoxaluria, and has symptoms including renal insufficiency, nephrocalcinosis and nephrolithiasis. An important gene associated with Hyperoxaluria, Primary, Type Ii is GRHPR (Glyoxylate And Hydroxypyruvate Reductase). The drugs Amoxicillin and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include kidney and endothelial.

UniProtKB/Swiss-Prot : 71 Hyperoxaluria primary 2: A disorder characterized by elevated urinary excretion of oxalate and L-glycerate, progressive tissue accumulation of insoluble calcium oxalate, nephrolithiasis, nephrocalcinosis, and end-stage renal disease.

Description from OMIM: 260000
GeneReviews: NBK2692

Related Diseases for Hyperoxaluria, Primary, Type Ii

Diseases in the Primary Hyperoxaluria family:

Hyperoxaluria, Primary, Type I Hyperoxaluria, Primary, Type Ii
Hyperoxaluria, Primary, Type Iii

Diseases related to Hyperoxaluria, Primary, Type Ii via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 d-glyceric aciduria 12.7
2 primary hyperoxaluria 11.5
3 hepatocellular carcinoma 10.3
4 hepatitis 10.3
5 blood group, i system 9.9
6 hermansky-pudlak syndrome 2 9.9
7 malaria 9.9

Graphical network of the top 20 diseases related to Hyperoxaluria, Primary, Type Ii:



Diseases related to Hyperoxaluria, Primary, Type Ii

Symptoms & Phenotypes for Hyperoxaluria, Primary, Type Ii

Symptoms via clinical synopsis from OMIM:

53
Genitourinary Kidneys:
hematuria
nephrocalcinosis
renal failure (in some patients)
calcium oxalate urolithiasis

Laboratory Abnormalities:
increased urinary oxylate
increased urinary l-glycerate
decreased grhpr activity


Clinical features from OMIM:

260000

Human phenotypes related to Hyperoxaluria, Primary, Type Ii:

55 31 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 55 31 occasional (7.5%) Occasional (29-5%) HP:0000083
2 nephrocalcinosis 55 31 hallmark (90%) Very frequent (99-80%) HP:0000121
3 nephrolithiasis 55 31 hallmark (90%) Very frequent (99-80%) HP:0000787
4 recurrent urinary tract infections 55 31 frequent (33%) Frequent (79-30%) HP:0000010
5 ureteral obstruction 55 31 frequent (33%) Frequent (79-30%) HP:0006000
6 hyperoxaluria 55 31 hallmark (90%) Very frequent (99-80%) HP:0003159
7 aminoaciduria 31 HP:0003355
8 hematuria 31 HP:0000790
9 calcium oxalate nephrolithiasis 31 HP:0008672

Drugs & Therapeutics for Hyperoxaluria, Primary, Type Ii

Drugs for Hyperoxaluria, Primary, Type Ii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
2
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
3
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
4
Rifabutin Approved, Investigational Phase 3 72559-06-9 6323490
5 Tocopherol Approved, Investigational, Nutraceutical Phase 2, Phase 3
6
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-02-9 14985
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
8
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 3 83-88-5 493570
9 tannic acid Approved, Nutraceutical Phase 3
10 Antioxidants Phase 2, Phase 3
11 Micronutrients Phase 2, Phase 3
12 Protective Agents Phase 2, Phase 3
13 Tocopherols Phase 2, Phase 3
14 Tocotrienols Phase 2, Phase 3
15 Trace Elements Phase 2, Phase 3
16 Vitamins Phase 2, Phase 3
17 Anti-Bacterial Agents Phase 3
18 Antibiotics, Antitubercular Phase 3
19 Antacids Phase 3
20 Anti-Infective Agents Phase 3
21 Antitubercular Agents Phase 3
22 Anti-Ulcer Agents Phase 3
23 Dermatologic Agents Phase 3
24 Gastrointestinal Agents Phase 3
25 Photosensitizing Agents Phase 3
26 Proton pump inhibitors Phase 3
27 Vitamin B Complex Phase 3
28 Tocotrienol Investigational, Nutraceutical Phase 2, Phase 3 6829-55-6
29 Folate Nutraceutical Phase 3
30 Vitamin B2 Nutraceutical Phase 3
31 Vitamin B9 Nutraceutical Phase 3
32
Iron Approved 7439-89-6 23925
33 ferric gluconate
34 Hematinics
35 carnitine Nutraceutical
36 lysine Nutraceutical
37 methionine Nutraceutical

Interventional clinical trials:

(show all 16)

# Name Status NCT ID Phase Drugs
1 Endothelial Function in a Sample Group of Patients From the ICARE Study Completed NCT00314379 Phase 2, Phase 3 Vitamin E 400IU/day
2 ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator Recruiting NCT03198507 Phase 3 RHB-105;Active Comparator
3 Haptoglobin and Diabetes Complications in Pregnancy Unknown status NCT01758016
4 The Type of Hepatoglobin in IUGR Unknown status NCT02127385
5 Effects of Carnitine on Oxidative Stress to IVIR Administration to CKD Patients:Impact of Haptoglobin Genotype Unknown status NCT02312414 L-Canitine
6 Cognitive Dysfunction in People Who Are Obese But Metabolically Healthy Unknown status NCT01928355
7 Effect of a Novel Nutraceutical on Weight Loss and Weight Maintenance in Obese Subjects Unknown status NCT01656681
8 Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana. Completed NCT01226368
9 Prevalence of Different Haptoglobin Phenotypes in Patients With COPD- Frequent Exacerbators Versus Non Exacerbators Completed NCT01745419
10 Haptoglobin Phenotype and Cardiovascular Complications in Diabetic Patients Completed NCT00448487
11 Effect of Sleep Apnea Treatment on Type 1 Diabetes Completed NCT02316665
12 Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial Recruiting NCT02776397
13 Severe Obesity Outcome Network Cohort (SOON) Recruiting NCT02264431
14 Rare Kidney Stone Consortium Biobank Recruiting NCT02026388
15 Associations Between Diabetes Care and Haptoglobin Genotype On outComes Active, not recruiting NCT00872456
16 International Registry for Primary Hyperoxaluria Withdrawn NCT00875823

Search NIH Clinical Center for Hyperoxaluria, Primary, Type Ii

Genetic Tests for Hyperoxaluria, Primary, Type Ii

Genetic tests related to Hyperoxaluria, Primary, Type Ii:

# Genetic test Affiliating Genes
1 Primary Hyperoxaluria, Type Ii 28 GRHPR

Anatomical Context for Hyperoxaluria, Primary, Type Ii

MalaCards organs/tissues related to Hyperoxaluria, Primary, Type Ii:

38
Kidney, Endothelial

Publications for Hyperoxaluria, Primary, Type Ii

Articles related to Hyperoxaluria, Primary, Type Ii:

(show all 29)
# Title Authors Year
1
Invited response to recurrence of oxalate nephropathy after isolated kidney transplantation for primary hyperoxaluria type 2. ( 29160959 )
2018
2
Recurrence of oxalate nephropathy after isolated kidney transplantation for primary hyperoxaluria type 2. ( 29068142 )
2018
3
Combined Liver-Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case Report. ( 28681512 )
2017
4
Severe child form of primary hyperoxaluria type 2 - a case report revealing consequence of GRHPR deficiency on metabolism. ( 28569194 )
2017
5
Calcified nodules on fingers in primary hyperoxaluria type 2. ( 26542998 )
2015
6
Failure of isolated kidney transplantation in a pediatric patient with primary hyperoxaluria type 2. ( 24597735 )
2014
7
Ethnic differences in GRHPR mutations in patients with primary hyperoxaluria type 2. ( 24116921 )
2013
8
Late diagnosis of primary hyperoxaluria type 2 in the adult: effect of a novel mutation in GRHPR gene on enzymatic activity and molecular modeling. ( 19296982 )
2009
9
A novel mutation in the GRHPR gene in a Japanese patient with primary hyperoxaluria type 2. ( 17510093 )
2007
10
Glyoxylate reductase activity in blood mononuclear cells and the diagnosis of primary hyperoxaluria type 2. ( 16597637 )
2006
11
Is liver analysis still required for the diagnosis of primary hyperoxaluria type 2? ( 16820377 )
2006
12
Tissue differences in the expression of mutations and polymorphisms in the GRHPR gene and implications for diagnosis of primary hyperoxaluria type 2. ( 16306119 )
2005
13
Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. ( 14635115 )
2003
14
Primary hyperoxaluria type 2 in children. ( 12185464 )
2002
15
Primary hyperoxaluria type 2 without L-glycericaciduria: is the disease under-diagnosed? ( 11477177 )
2001
16
Novel mutation in the GRHPR gene in a Chinese patient with primary hyperoxaluria type 2 requiring renal transplantation from a living related donor. ( 11728965 )
2001
17
Recent developments in our understanding of primary hyperoxaluria type 2. ( 10541261 )
1999
18
Kinetic analysis and tissue distribution of human D-glycerate dehydrogenase/glyoxylate reductase and its relevance to the diagnosis of primary hyperoxaluria type 2. ( 9463747 )
1998
19
Primary hyperoxaluria type 2: enzymology. ( 9604806 )
1998
20
Nephrocalcinosis in a patient with primary hyperoxaluria type 2. ( 9090680 )
1997
21
Primary hyperoxaluria type 2. ( 9243228 )
1997
22
Nephrocalcinosis in a patient with primary hyperoxaluria type 2. ( 8865239 )
1996
23
Detection of primary hyperoxaluria type 2 (L-glyceric aciduria) in patients with maintained renal function or end-stage renal failure. ( 8538930 )
1995
24
Primary hyperoxaluria type 2. ( 8592629 )
1995
25
End-stage renal failure in primary hyperoxaluria type 2. ( 8177288 )
1994
26
Primary Hyperoxaluria Type 2 ( 20301742 )
1993
27
High-performance liquid chromatographic assay for L-glyceric acid in body fluids. Application in primary hyperoxaluria type 2. ( 1458609 )
1992
28
Enzymological characterization of a feline analogue of primary hyperoxaluria type 2: a model for the human disease. ( 2516173 )
1989
29
L-Glyceric aciduria (primary hyperoxaluria type 2) in siblings in two unrelated families. ( 6434867 )
1984

Variations for Hyperoxaluria, Primary, Type Ii

ClinVar genetic disease variations for Hyperoxaluria, Primary, Type Ii:

6 (show all 40)
# Gene Variation Type Significance SNP ID Assembly Location
1 GRHPR NM_012203.1(GRHPR): c.864_865delTG (p.Val289Aspfs) deletion Pathogenic/Likely pathogenic rs180177321 GRCh37 Chromosome 9, 37432134: 37432135
2 GRHPR NM_012203.1(GRHPR): c.248_249delTG (p.Val83Glyfs) deletion Pathogenic rs672601351 GRCh38 Chromosome 9, 37425955: 37425956
3 GRHPR NM_012203.1(GRHPR): c.904C> T (p.Arg302Cys) single nucleotide variant Pathogenic rs180177322 GRCh38 Chromosome 9, 37436699: 37436699
4 GRHPR NM_012203.1(GRHPR): c.337G> A (p.Glu113Lys) single nucleotide variant Pathogenic/Likely pathogenic rs180177307 GRCh37 Chromosome 9, 37426584: 37426584
5 GRHPR NM_012203.1(GRHPR): c.103delG (p.Asp35Thrfs) deletion Pathogenic rs80356708 GRCh37 Chromosome 9, 37424861: 37424861
6 GRHPR NM_012203.1(GRHPR): c.295C> T (p.Arg99Ter) single nucleotide variant Pathogenic rs119490108 GRCh37 Chromosome 9, 37426542: 37426542
7 GRHPR NM_012203.1(GRHPR): c.-4_-3delGCinsAT indel Pathogenic rs796052077 GRCh37 Chromosome 9, 37422744: 37422745
8 GRHPR NM_012203.1(GRHPR): c.45delA (p.Ala17Profs) deletion Pathogenic rs180177311 GRCh37 Chromosome 9, 37422792: 37422792
9 GRHPR NM_012203.1(GRHPR): c.84-2A> G single nucleotide variant Pathogenic rs180177319 GRCh37 Chromosome 9, 37424840: 37424840
10 GRHPR NM_012203.1(GRHPR): c.102G> A (p.Trp34Ter) single nucleotide variant Pathogenic rs180177304 GRCh37 Chromosome 9, 37424860: 37424860
11 GRHPR NM_012203.1(GRHPR): c.203T> C (p.Leu68Pro) single nucleotide variant Pathogenic rs180177305 GRCh37 Chromosome 9, 37424961: 37424961
12 GRHPR NM_012203.1(GRHPR): c.287G> T (p.Arg96Leu) single nucleotide variant Pathogenic rs796052078 GRCh37 Chromosome 9, 37425991: 37425991
13 GRHPR NM_012203.1(GRHPR): c.288-2_288delAGT deletion Pathogenic rs796052081 GRCh37 Chromosome 9, 37426533: 37426535
14 GRHPR NM_012203.1(GRHPR): c.375delG (p.Leu126Cysfs) deletion Pathogenic rs180177308 GRCh37 Chromosome 9, 37426622: 37426622
15 GRHPR NM_012203.1(GRHPR): c.404+3_404+6delAAGT deletion Pathogenic/Likely pathogenic rs180177309 GRCh37 Chromosome 9, 37426654: 37426657
16 GRHPR NM_012203.1(GRHPR): c.478G> A (p.Gly160Arg) single nucleotide variant Pathogenic rs180177312 GRCh37 Chromosome 9, 37428554: 37428554
17 GRHPR NM_012203.1(GRHPR): c.493+2T> A single nucleotide variant Pathogenic/Likely pathogenic rs180177313 GRCh37 Chromosome 9, 37428571: 37428571
18 GRHPR NM_012203.1(GRHPR): c.494G> A (p.Gly165Asp) single nucleotide variant Pathogenic rs180177314 GRCh37 Chromosome 9, 37429729: 37429729
19 GRHPR NM_012203.1(GRHPR): c.540delT (p.Leu181Cysfs) deletion Pathogenic rs180177315 GRCh37 Chromosome 9, 37429775: 37429775
20 GRHPR NM_012203.1(GRHPR): c.608_609delCT (p.Pro203Argfs) deletion Pathogenic rs180177316 GRCh37 Chromosome 9, 37430517: 37430518
21 GRHPR NM_012203.1(GRHPR): c.694delC (p.Gln232Argfs) deletion Pathogenic rs796052082 GRCh38 Chromosome 9, 37430606: 37430606
22 GRHPR NM_012203.1(GRHPR): c.735-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs180177317 GRCh37 Chromosome 9, 37432004: 37432004
23 GRHPR NM_012203.1(GRHPR): c.743T> A (p.Val248Asp) single nucleotide variant Pathogenic rs796052079 GRCh37 Chromosome 9, 37432013: 37432013
24 GRHPR NM_012203.1(GRHPR): c.905G> A (p.Arg302His) single nucleotide variant Pathogenic rs180177323 GRCh38 Chromosome 9, 37436700: 37436700
25 GRHPR NM_012203.1(GRHPR): c.934A> G (p.Asn312Asp) single nucleotide variant Pathogenic rs180177324 GRCh38 Chromosome 9, 37436729: 37436729
26 GRHPR NM_012203.1(GRHPR): c.965T> C (p.Met322Thr) single nucleotide variant Pathogenic rs180177325 GRCh37 Chromosome 9, 37436757: 37436757
27 GRHPR NM_012203.1(GRHPR): c.965T> G (p.Met322Arg) single nucleotide variant Pathogenic rs180177325 GRCh37 Chromosome 9, 37436757: 37436757
28 GRHPR NG_008135.1 insertion Pathogenic
29 GRHPR NM_012203.1(GRHPR): c.154delG (p.Ala52Profs) deletion Likely pathogenic rs1057517216 GRCh38 Chromosome 9, 37424915: 37424915
30 GRHPR NM_012203.1(GRHPR): c.214+2T> G single nucleotide variant Likely pathogenic rs1057517398 GRCh37 Chromosome 9, 37424974: 37424974
31 GRHPR NM_012203.1(GRHPR): c.228dupA (p.Val77Serfs) duplication Likely pathogenic rs1057517238 GRCh38 Chromosome 9, 37425935: 37425935
32 GRHPR NM_012203.1(GRHPR): c.337G> T (p.Glu113Ter) single nucleotide variant Likely pathogenic rs180177307 GRCh38 Chromosome 9, 37426587: 37426587
33 GRHPR NM_012203.1(GRHPR): c.404delA (p.Asn135Metfs) deletion Likely pathogenic rs1057516299 GRCh38 Chromosome 9, 37426654: 37426654
34 GRHPR NM_012203.1(GRHPR): c.435_436delGC (p.Trp145Cysfs) deletion Likely pathogenic rs1057517333 GRCh38 Chromosome 9, 37428514: 37428515
35 GRHPR NM_012203.1(GRHPR): c.441_442delTG (p.Cys147Trpfs) deletion Likely pathogenic rs1057517026 GRCh38 Chromosome 9, 37428520: 37428521
36 GRHPR NM_012203.1(GRHPR): c.454dupA (p.Thr152Asnfs) duplication Likely pathogenic rs1057516941 GRCh37 Chromosome 9, 37428530: 37428530
37 GRHPR NM_012203.1(GRHPR): c.515delT (p.Leu172Argfs) deletion Likely pathogenic rs1057516990 GRCh38 Chromosome 9, 37429753: 37429753
38 GRHPR NM_012203.1(GRHPR): c.597delT (p.Phe199Leufs) deletion Likely pathogenic rs1057516292 GRCh37 Chromosome 9, 37429832: 37429832
39 GRHPR NM_012203.1(GRHPR): c.755dupA (p.Asp252Glufs) duplication Likely pathogenic rs1057516823 GRCh38 Chromosome 9, 37432028: 37432028
40 GRHPR NM_012203.1(GRHPR): c.954delA (p.Glu320Serfs) deletion Likely pathogenic rs1057516831 GRCh37 Chromosome 9, 37436746: 37436746

Expression for Hyperoxaluria, Primary, Type Ii

Search GEO for disease gene expression data for Hyperoxaluria, Primary, Type Ii.

Pathways for Hyperoxaluria, Primary, Type Ii

GO Terms for Hyperoxaluria, Primary, Type Ii

Sources for Hyperoxaluria, Primary, Type Ii

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....